Covid-19 + Influenza A/B + RSV + Adenovirus Combo Rapid Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A (including the subtype H1N1), influenza B, respiratory syncytial and adenovirus virus in nasal swab specimens from symptomatic and asymptomatic patients. It is intended to aid in the rapid diagnosis of SARS-CoV-2, influenza A, influenza B, respiratory syncytial and adenovirus virus infections in the healthcare setting management, general population screening, workplace screening, etc. It is intended to be used by a trained healthcare professional, member of the allied health professions, and trained lay-person at point-of-care, near-patient, and laboratory-based testing.

This test provides only a preliminary test result. Therefore, any reactive specimen with the Covid-19 + Influenza A/B + RSV+ Adenovirus Combo Rapid Test must be confirmed with alternative testing method(s) and clinical findings.